Skip to main content

Examining Improved Survival, Response Rates Among Patients With Breast Cancer

June 24, 2020

php logoSara Hurvitz, MD, medical oncologist, Ronald Reagan UCLA Medical Center, and Sherene Loi, PhD, senior medical oncologist, Peter MacCallum Cancer Center, discuss their recent study, HER2CLIMB, highlighting the positive findings that include the reduction of intracranial progression and death among patients with breast cancer treated with tucatinib. 


Lin NU, Murthy RK, Anders CK, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). J Clin Oncol. 38: 2020 (suppl; abstr 1005). doi: 10.1200/JCO.2020.38.15_suppl.1005  

Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
5 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top